SPY376.61-7.18 -1.87%
DIA304.81-4.58 -1.48%
IXIC13,412.08-213.99 -1.57%

Goldman Sachs Initiates Coverage On Harmony Biosciences with Neutral Rating, Announces Price Target of $43

Goldman Sachs initiates coverage on Harmony Biosciences (NASDAQ:HRMY) with a Neutral rating and announces Price Target of $43.

· 09/14/2020 07:27
Goldman Sachs initiates coverage on Harmony Biosciences (NASDAQ:HRMY) with a Neutral rating and announces Price Target of $43.